BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 23984804)

  • 1. Agonists of luteinizing hormone-releasing hormone in prostate cancer.
    Rick FG; Block NL; Schally AV
    Expert Opin Pharmacother; 2013 Nov; 14(16):2237-47. PubMed ID: 23984804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer.
    Rick FG; Schally AV
    Urol Oncol; 2015 Jun; 33(6):270-4. PubMed ID: 25512159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
    Clinton TN; Woldu SL; Raj GV
    Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of LHRH antagonists in the treatment of prostate cancer.
    Crawford ED; Hou AH
    Oncology (Williston Park); 2009 Jun; 23(7):626-30. PubMed ID: 19626830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Traditional androgen ablation approaches to advanced prostate cancer: new insights.
    Rove KO; Crawford ED
    Can J Urol; 2014 Apr; 21(2 Supp 1):14-21. PubMed ID: 24775719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
    BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation therapy: past, present and future.
    Schröder F; Crawford ED; Axcrona K; Payne H; Keane TE
    BJU Int; 2012 Jun; 109 Suppl 6():1-12. PubMed ID: 22672120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
    Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of LHRH antagonists for advanced prostate cancer.
    Moul JW
    Can J Urol; 2014 Apr; 21(2 Supp 1):22-7. PubMed ID: 24775720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
    Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
    Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Exist a Differential Impact of Degarelix
    Sciarra A; Busetto GM; Salciccia S; Del Giudice F; Maggi M; Crocetto F; Ferro M; De Berardinis E; Scarpa RM; Porpiglia F; Carmignani L; Damiano R; Artibani W; Carrieri G
    Front Endocrinol (Lausanne); 2021; 12():695170. PubMed ID: 34194398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects.
    Walker LM; Tran S; Robinson JW
    Clin Genitourin Cancer; 2013 Dec; 11(4):375-84. PubMed ID: 23891497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.
    Klotz L
    Expert Opin Drug Metab Toxicol; 2015; 11(11):1795-802. PubMed ID: 26513436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth.
    Krakowsky Y; Morgentaler A
    Eur Urol Focus; 2019 Jan; 5(1):81-89. PubMed ID: 28753828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.
    Engel JB; Schally AV
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):157-67. PubMed ID: 17237842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.